DexCom Inc Net Assets
DexCom Inc net assets. Based on the latest financial reports, DexCom Inc (DXCM) has net assets worth $2.96 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.63 Billion) and total liabilities ($3.68 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore DXCM year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.96 Billion |
| % of Total Assets | 44.58% |
| Annual Growth Rate | N/A |
| 5-Year Change | 34.47% |
| 10-Year Change | 867.58% |
| Growth Volatility | 158.48 |
Net Assets of DexCom Inc (2003–2025)
Net assets of DexCom Inc from 2003 to 2025. This chart illustrates how DexCom Inc's net assets have evolved over time, based on quarterly financial data. See DexCom Inc net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for DexCom Inc (2003–2025)
The table below shows the annual net assets of DexCom Inc from 2003 to 2025. For live market cap and overall valuation, see market value of DexCom Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.75 Billion | +30.60% |
| 2024-12-31 | $2.10 Billion | +1.64% |
| 2023-12-31 | $2.07 Billion | -2.96% |
| 2022-12-31 | $2.13 Billion | +4.39% |
| 2021-12-31 | $2.04 Billion | +11.80% |
| 2020-12-31 | $1.83 Billion | +106.95% |
| 2019-12-31 | $882.60 Million | +33.06% |
| 2018-12-31 | $663.30 Million | +58.15% |
| 2017-12-31 | $419.40 Million | +47.78% |
| 2016-12-31 | $283.80 Million | +28.30% |
| 2015-12-31 | $221.20 Million | +57.77% |
| 2014-12-31 | $140.20 Million | +66.71% |
| 2013-12-31 | $84.10 Million | +9.22% |
| 2012-12-31 | $77.00 Million | -26.31% |
| 2011-12-31 | $104.49 Million | +71.31% |
| 2010-12-31 | $60.99 Million | +430.67% |
| 2009-12-31 | $-18.45 Million | +52.23% |
| 2008-12-31 | $-38.61 Million | -642.70% |
| 2007-12-31 | $7.12 Million | -87.48% |
| 2006-12-31 | $56.83 Million | +15.01% |
| 2005-12-31 | $49.41 Million | +200.21% |
| 2004-12-31 | $-49.31 Million | -51.25% |
| 2003-12-31 | $-32.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to DexCom Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 243390000000.0% over the analyzed period, indicating profitable operations and earnings retention.
DexCom Inc Net Assets Breakdown (December 2025)
DexCom Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.43 Billion | 88.63% |
| Common Stock | $400.00K | 0.01% |
| Other Comprehensive Income | $115.00 Million | 4.19% |
| Other Components | $196.70 Million | 7.16% |
| Total Equity | $2.75 Billion | 100.00% |
DexCom Inc Competitors by Market Cap
The table below lists competitors of DexCom Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KONE Oyj
HE:KNEBV
|
$28.58 Billion |
|
Sandoz Group AG
SW:SDZ
|
$28.58 Billion |
|
Mettler-Toledo International Inc
NYSE:MTD
|
$28.64 Billion |
|
Atmos Energy Corporation
NYSE:ATO
|
$28.78 Billion |
|
Jabil Circuit Inc
NYSE:JBL
|
$28.58 Billion |
|
Heidelberg Materials AG
XETRA:HEI
|
$28.48 Billion |
|
Banco Bradesco S.A
F:BREC
|
$28.47 Billion |
|
TDK Corporation
F:TDKA
|
$28.47 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DexCom Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,102,600,000 to 2,746,000,000, a change of 643,400,000 (30.6%).
- Net income of 836,300,000 contributed positively to equity growth.
- Share repurchases of 500,000,000 reduced equity.
- New share issuances of 28,100,000 increased equity.
- Other comprehensive income increased equity by 123,000,000.
- Other factors increased equity by 156,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $836.30 Million | +30.46% |
| Share Repurchases | $500.00 Million | -18.21% |
| Share Issuances | $28.10 Million | +1.02% |
| Other Comprehensive Income | $123.00 Million | +4.48% |
| Other Changes | $156.00 Million | +5.68% |
| Total Change | $- | 30.60% |
Book Value vs Market Value Analysis
This analysis compares DexCom Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-0.46 | $82.29 | x |
| 2001-12-31 | $-1.18 | $82.29 | x |
| 2003-12-31 | $-3.76 | $82.29 | x |
| 2004-12-31 | $-5.39 | $82.29 | x |
| 2005-12-31 | $0.65 | $82.29 | x |
| 2006-12-31 | $0.52 | $82.29 | x |
| 2007-12-31 | $0.06 | $82.29 | x |
| 2008-12-31 | $-0.17 | $82.29 | x |
| 2009-12-31 | $-0.10 | $82.29 | x |
| 2010-12-31 | $0.27 | $82.29 | x |
| 2011-12-31 | $0.40 | $82.29 | x |
| 2012-12-31 | $0.28 | $82.29 | x |
| 2013-12-31 | $0.30 | $82.29 | x |
| 2014-12-31 | $0.47 | $82.29 | x |
| 2015-12-31 | $0.69 | $82.29 | x |
| 2016-12-31 | $0.85 | $82.29 | x |
| 2017-12-31 | $1.21 | $82.29 | x |
| 2018-12-31 | $1.88 | $82.29 | x |
| 2019-12-31 | $2.39 | $82.29 | x |
| 2020-12-31 | $4.68 | $82.29 | x |
| 2021-12-31 | $4.76 | $82.29 | x |
| 2022-12-31 | $4.99 | $82.29 | x |
| 2023-12-31 | $4.86 | $82.29 | x |
| 2024-12-31 | $5.09 | $82.29 | x |
| 2025-12-31 | $6.77 | $82.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DexCom Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 30.46%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.94%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 2.31x
- Recent ROE (30.46%) is above the historical average (-39.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.65 Million |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.38 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.65 Million |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.02 Million |
| 2005 | -62.27% | 0.00% | 0.00x | 1.15x | $-35.71 Million |
| 2006 | -82.00% | -2147.64% | 0.03x | 1.14x | $-52.28 Million |
| 2007 | -644.81% | -991.53% | 0.06x | 10.86x | $-46.59 Million |
| 2008 | 0.00% | -560.93% | 0.22x | 0.00x | $-53.24 Million |
| 2009 | 0.00% | -180.26% | 0.63x | 0.00x | $-51.68 Million |
| 2010 | -90.45% | -113.45% | 0.63x | 1.27x | $-61.27 Million |
| 2011 | -42.82% | -58.67% | 0.63x | 1.15x | $-55.20 Million |
| 2012 | -70.78% | -54.55% | 0.94x | 1.38x | $-62.20 Million |
| 2013 | -35.43% | -18.63% | 1.31x | 1.46x | $-38.21 Million |
| 2014 | -15.98% | -8.64% | 1.40x | 1.32x | $-36.42 Million |
| 2015 | -26.04% | -14.33% | 1.38x | 1.32x | $-79.72 Million |
| 2016 | -23.11% | -11.44% | 1.42x | 1.42x | $-93.98 Million |
| 2017 | -11.97% | -6.99% | 0.79x | 2.16x | $-92.14 Million |
| 2018 | -19.16% | -12.32% | 0.54x | 2.89x | $-193.43 Million |
| 2019 | 11.45% | 6.85% | 0.62x | 2.71x | $12.84 Million |
| 2020 | 27.02% | 25.62% | 0.45x | 2.35x | $310.95 Million |
| 2021 | 10.62% | 8.86% | 0.50x | 2.42x | $12.69 Million |
| 2022 | 16.01% | 11.73% | 0.54x | 2.53x | $128.02 Million |
| 2023 | 26.18% | 14.95% | 0.58x | 3.03x | $334.64 Million |
| 2024 | 27.40% | 14.29% | 0.62x | 3.08x | $365.94 Million |
| 2025 | 30.46% | 17.94% | 0.74x | 2.31x | $561.70 Million |
Industry Comparison
This section compares DexCom Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,883,148,510
- Average return on equity (ROE) among peers: -152.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DexCom Inc (DXCM) | $2.96 Billion | 0.00% | 1.24x | $28.58 Billion |
| Abbott Laboratories (ABT) | $38.83 Billion | 14.74% | 0.89x | $184.67 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $2.26 Million |
| Aethlon Medical Inc (AEMD) | $5.12 Million | -261.31% | 0.44x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $786.82 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $1.53 Million | -361.86% | 1.36x | $2.20 Million |
| Allurion Technologies, Inc. (ALUR) | $-34.28 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $1.96 Million | -680.21% | 0.05x | $1.76 Million |
| Artivion Inc (AORT) | $6.60 Million | -10.61% | 0.65x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $6.01 Million | -36.31% | 0.22x | $109.52 Million |
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more